Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Men receiving treatment for prostate cancer often face challenges that extend well beyond the disease itself. A new study led ...

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk prostate cancer.

PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...

ADT with leuprolide was tied to increased coronary plaque vs relugolix in prostate cancer. What does this mean for CV risk?

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...